Novo Nordisk CEO Defends Wegovy Pill Pricing as a Responsibility, Not a Gamble

Novo Nordisk, the global pharmaceutical leader, has reaffirmed its stance on the pricing of its Wegovy pill, a breakthrough obesity treatment. CEO Lars Fruergaard Jørgensen clarified that the company does not view its pricing approach as a gamble, but rather as a responsibility to deliver essential medications to patients worldwide.

The statement comes amid growing scrutiny of drug affordability and accessibility, particularly in the obesity and metabolic care segment. Novo Nordisk’s strategy highlights its balance between innovation, patient access, and sustainable business practices.

Key Highlights:

• CEO Statement: Pricing strategy for Wegovy pill is framed as responsibility, not risk.
• Patient-Centric Approach: Focus on ensuring medications reach all people in need.
• Global Impact: Wegovy addresses rising obesity rates, a major global health challenge.
• Strategic Balance: Commitment to affordability while sustaining innovation and R&D.
• Healthcare Responsibility: Reinforces Novo Nordisk’s mission to improve lives through accessible treatments.

This announcement underscores Novo Nordisk’s role as a responsible healthcare innovator, aiming to expand access to obesity treatments while maintaining long-term sustainability.

Sources: Reuters, Bloomberg, Business Standard